STOCK TITAN

SAB BIOTHERAPEUTICS INC - SABS STOCK NEWS

Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.

SAB Biotherapeutics (Nasdaq: SABS) is a clinical-stage biopharmaceutical leader advancing novel immunotherapies through its DiversitAb platform. This page provides investors and industry professionals with timely updates on clinical developments, financial announcements, and strategic initiatives.

Access official press releases, trial milestones, and partnership announcements in one centralized hub. Our curated news collection covers critical updates including FDA communications, research breakthroughs, and quarterly earnings reports—all essential for tracking SABS's progress in treating type 1 diabetes and autoimmune disorders.

Discover how SAB BIO's transchromosomic cattle technology enables rapid production of fully human antibodies, with updates on lead candidate SAB-142 and pipeline expansion. Bookmark this page for direct access to verified information supporting data-driven investment and research decisions.

Rhea-AI Summary

SAB Biotherapeutics presented data on its polyclonal antibodies, SAB-176 for influenza and SAB-185 for COVID-19, demonstrating significant efficacy against highly mutating viruses at the 2022 Plasma Product Biotechnology Conference. The DiversitAb™ platform allows production of human antibodies without needing blood donations, enhancing safety and potency. Phase 2 results indicate SAB-185 effectively neutralizes multiple SARS-CoV-2 variants, while SAB-176 significantly reduced viral loads in H1N1 challenged adults, supporting its potential in treating respiratory diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
none
-
Rhea-AI Summary

SAB Biotherapeutics (SABS) has entered an exclusive manufacturing services agreement with Emergent BioSolutions (EBS) to support the production of their fully-human polyclonal antibody products. This collaboration enables SAB to focus on R&D while Emergent provides end-to-end cGMP manufacturing services. SAB's immunotherapy platform utilizes transchromosomic cows to create targeted, high-potency antibodies for various diseases, including influenza and C. diff. The financial terms of the agreement were not disclosed, but it marks a strategic advancement for SAB's clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
partnership
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced significant findings from its polyclonal antibody platform at the OPTIONS XI conference in Belfast. New data revealed that SAB-176 effectively reduced H1N1 viral load and improved symptoms in a Phase 2a trial. Additionally, the SAB-185 candidate demonstrated efficacy against various SARS-CoV-2 variants. Both therapeutic candidates showcased the platform's ability to neutralize rapidly mutating viruses, reinforcing SAB's innovative position in immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
covid-19
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced its participation in the OPTIONS XI conference from Sept. 26-29, 2022, in Belfast, Northern Ireland. The company will present new data on its fully-human polyclonal antibody platform, specifically during an oral presentation of SAB-176's efficacy against Type A and B influenza. This Phase 2a trial targets H1N1 challenged adults. Additionally, a poster will detail the protective effects of transchromosomic bovine-derived antibodies against multiple SARS-CoV-2 variants. These presentations highlight SAB's innovative immunotherapeutic approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
conferences clinical trial covid-19
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) reported its Q2 2022 financial results, highlighting a cash position of $16.6 million and a net loss of $4.8 million with EPS of $(0.11). Operating expenses are projected to be covered for the next twelve months. The company is advancing its pipeline with SAB 176 for anti-influenza entering Phase II development and SAB 195 targeting C. diff. moving towards pre-IND. A virtual R&D update is scheduled for August 17, 2022, to showcase its polyclonal immunotherapy platform, DiversitAb™.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
-
Rhea-AI Summary

SAB Biotherapeutics (SABS) has terminated its agreement with the U.S. Department of Defense due to misalignment of goals following modifications during the COVID-19 pandemic. This allows SAB to refocus on its core mission and advance its research pipeline, including the development of SAB-195, a polyclonal antibody treatment for Clostridioides difficile infection (CDI), which affects 500,000 people annually in the U.S. alone. SAB plans to file an IND within 18 months and anticipates announcing Phase 1 clinical trial results in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
none
Rhea-AI Summary

SAB Biotherapeutics (NASDAQ: SABS) announced a Virtual 2022 Annual R&D Portfolio Update on August 17, 2022, at 10:30 a.m. ET. The update will showcase the company's unique DiversitAb™ immunotherapy platform that produces high-potency, fully-human polyclonal antibodies without human donors. Executives will discuss planned clinical and preclinical development programs targeting diseases like COVID-19 and type 1 diabetes. A live webcast will be available, with a replay on the company's website. For registration details, visit www.sab.bio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
conferences
-
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Rear Admiral Scott Giberson to its Board of Directors, effective July 7, 2022. Giberson, a retired two-star admiral with extensive government and healthcare experience, will bring valuable insights to the company. His previous roles include Deputy Surgeon General and Commander of the Commissioned Corps’ Ebola Response. SAB aims to leverage Giberson’s expertise to address unmet medical needs through its innovative immunotherapy platform. The company focuses on developing fully human polyclonal antibodies targeting diseases like COVID-19 and type 1 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
management
-
Rhea-AI Summary

SAB Biotherapeutics (SABS) hosted Congressmen Dusty Johnson and Dean Phillips on July 1, 2022, at its Sioux Falls facility. The visit showcased SAB's innovative immunotherapy platform that produces fully human polyclonal antibodies through genetically engineered cattle. The Congressmen engaged with SAB's management team, discussing advancements in COVID-19 treatment and the company's pipeline targeting influenza, oncology, and type 1 diabetes. SAB aims to address unmet global health needs with its DiversitAb™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Dr. Alexandra Kropotova as Chief Medical Officer to enhance its pipeline in immune and autoimmune disorders. With over 20 years of experience, Dr. Kropotova previously led drug development at Teva Pharmaceuticals and has held key roles at Sanofi and Pfizer. Her expertise is expected to be vital for advancing SAB's initiatives in areas such as infectious diseases and cancer. The company continues to leverage its innovative platform for producing high-potency, fully human polyclonal antibodies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
management

FAQ

What is the current stock price of SAB BIOTHERAPEUTICS (SABS)?

The current stock price of SAB BIOTHERAPEUTICS (SABS) is $1.7899 as of April 28, 2025.

What is the market cap of SAB BIOTHERAPEUTICS (SABS)?

The market cap of SAB BIOTHERAPEUTICS (SABS) is approximately 13.2M.
SAB BIOTHERAPEUTICS INC

Nasdaq:SABS

SABS Rankings

SABS Stock Data

13.16M
7.81M
19.15%
28.69%
1.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MIAMI BEACH